Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3381-3388

  Efficace, Fabio ^a   Therasse, Patrick ^a   Piccart, Martine J ^a   Coens, Corneel ^a   Van Steen, Kristel ^a   Welnicka Jaskiewicz, Marzena ^a   Cufer, Tanja ^a   Dyczka, Jaroslaw ^a   Lichinitser, Michail ^a   Shepherd, Lois ^a   de Haes, Hanneke ^a   Sprangers, Mirjam A ^a   Bottomley, Andrew ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MASTITIS; MEDICAL ASSESSMENT; MEDICAL LITERATURE; METASTASIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OBSERVATION; PATIENT SELECTION; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCORING SYSTEM; SURVIVAL TIME; TREATMENT OUTCOME; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HEALTH STATUS; INFLAMMATION; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTION AND FORECASTING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH STATUS; HUMANS; INFLAMMATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY OF LIFE;

EID: 4344714932     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.060     Document Type: Article

References (35)

1. Priestman TJ, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1:899-900, 1976
2. Dancey J, Zee B, Osoba D, et al: Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 6:151-158, 1997
3. Coates A, Porzsolt F, Osoba D: Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33:1025-1030, 1997
4. Seidman AD, Portenoy R, Yao TJ, et al: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87:1316-1322, 1995
5. Chiarion-Sileni V, Del Bianco P, De Salvo GL, et al: Quality of life evaluation in a randomised trial of chemotherapy versus biochemotherapy in advanced melanoma patients. Eur J Cancer 39:1577-1585, 2003
6. de Graeff A, de Leeuw JR, Ros WJ, et al: Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 37:332-339, 2001
7. Blazeby JM, Brookes ST, Alderson D: The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49:227-230, 2001
8. Maisey NR, Norman A, Watson M, et al: Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38:1351-1357, 2002
9. Herndon JE II, Fleishman S, Kornblith AB, et al: Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85:333-340, 1999
10. Coates A, Thomson D, McLeod GR, et al: Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A:1731-1734, 1993
11. Kramer JA, Curran D, Piccart M, et al: Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498-1506, 2000
12. Coates AS, Hurny C, Peterson HF, et al: Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18:3768-3774, 2000
13. Luoma ML, Hakamies-Blomqvist L, Sjöström J, et al: Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39:1370-1376, 2003
14. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833-1838, 1992
15. Tross S, Herndon J II, Korzun A, et al: Psychological symptoms and disease-free and overall survival in women with stage II breast cancer: Cancer and Leukemia Group B. J Natl Cancer Inst 88:661-667, 1996
16. Mulder CL, Van der Pompe G, Spiegel D, et al: Do psychosocial factors influence the course of breast cancer? Psychooncology 1:155-167, 1992
17. Van Steen K, Curran D, Kramer J, et al: Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Stat Med 21:3865-3884, 2002
18. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 11:2093-2109, 1992
19. Schumacher M, Hollander N, Sauerbrei W: Resampling and crossvalidation techniques: A tool to reduce bias caused by model building? Stat Med 16:2813-2827, 1997
20. Augustin NH, Sauerbrei W, Schumacher M: Incorporating model selection into prognostic factor model predictions: Freiburg Center for Data Analysis and Modeling, Preprint 76, 2002. http://www.fdm.uni-freiburg.de/pub/preprints.php
21. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
22. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
23. Hakamies-Blomqvist L, Luoma ML, Sjostrom J, et al: Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs 35:709-716, 2001
24. Casciato DA, Lowitz BB: Manual of Clinical Oncology (ed 4). Philadelphia, PA, Lippnicott Williams & Wilkins, 2000
25. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, EORTC Publications, 2001
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Friedman M: The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc 32:675-701, 1937
28. Cox DR: Regression models and life tables. J R Stat Soc 4:187-220, 1972
29. Hess KR: Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14:1707-1723, 1995
30. Razavi D, Farvacques C, Delvaux N, et al: Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet 335:931-933, 1990
31. Efficace F, Biganzoli L, Piccart M, et al: Baseline health-related quality of life data as prognostic factors in a phase III multicenter study of women with metastatic breast cancer. Eur J Cancer 40:1021-1030, 2004
32. Sprangers MA: Quality of life assessment in oncology: Achievements and challenges. Acta Oncol 41:229-237, 2002
33. Osoba D: Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608-616, 1994
34. Osoba D, Slamon DJ, Burchmore M, et al: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20:3106-3113, 2002
35. Earlam S, Glover C, Fordy C, et al: Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14:171-175, 1996